The drugmaker is reportedly accused of excessive pricing for anti-TB drug bedaquiline and patent evergreening
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
A WIPO committee meets this week to debate a draft text that would require patent filers to disclose their use of genetic resources and associated traditional knowledge
The UPC will decide whether to grant 10x Genomics a preliminary injunction against Nanostring on September 19
The Taiwanese biotech firm is the first commercial entity to share IP and know-how via a WHO pool set up in 2020
A statement from health ministers arrived as negotiations over pandemic prevention measures continue at the WHO
Samsung Bioepis’s biosimilar of a drug used to treat a rare blood disorder will remain on the German market
The Munich Regional Court has already granted a preliminary injunction restricting the sale of Amgen’s biosimilar version of orphan drug Soliris
Alexion obtained a preliminary injunction in Munich barring Amgen from selling a biosimilar version of its antibody drug
The Delhi High Court said third parties who use different processes to make a patented product can’t be restricted if the plaintiff’s registration covers a product-by-process patent
J&J has granted licences to the Stop TB Partnership after months of campaigner pressure over its patent strategy
The Court of Appeal had stern words for Med-El’s representatives after they highlighted a deputy judge’s background as a solicitor
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyJianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement
-
Sponsored by Purplevine IPXiaojuan Yu of Purplevine IP Group discusses the medical device industry in China and considers why changes to the law are welcomed
-
Sponsored by FB RiceLee Miles of FB Rice discusses Australia’s patent box scheme which is set to introduce the agricultural and low emissions technology sectors
-
Sponsored by Gün and PartnersBarış Kalaycı and Direnç Bada of Gün and Partners discuss an IP case that led to the discovery, and removal, of fake fire-resistant glass from hospitals in Turkey
-
Sponsored by Wanhuida Intellectual PropertyThe China Patent Office upheld the validity of the patent over the antihistamine desloratadine citrate disodium, as Yue Guan from Wanhuida Intellectual Property explains
-
Sponsored by Remfry & SagarShukadev Khuraijam and Ankush Verma of Remfry & Sagar discuss pre-grant straw man oppositions in India and the impact of a recent decision of the Bombay High Court
-
Sponsored by LexOrbisManisha Singh and Pradeep Kumar Kamal of LexOrbis explain how India has adopted a unique solution to protecting the rights of plant breeders and farmers
-
Sponsored by Gün and PartnersAysel Korkmaz Yatkın and Fatma Sevde Tan of Gün and Partners discuss a welcome decision that reinforces patent owners’ right to information about pharmaceutical licensing applications in Turkey
-
Sponsored by Wanhuida Intellectual PropertyXiaohui Wu, Yuming Wang and Jianhui Li of Wanhuida Intellectual Property discuss the Supreme People’s Court’s first decision in parallel civil and administrative proceedings involving a chiral drug patent
A recent decision makes obviousness-type double patenting a real concern for applicants but some sources think a Supreme Court review is on the cards
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Samantak Ghosh, senior IP counsel at Gilead, talks about his pivot from research to law, the rise of biologics, and his pro bono work
The ‘M’ in the company’s ‘COVID MVAX’ applied-for trademark could help it prevail against claims of genericism, though the outcome is still uncertain, say counsel
Interviews; Exclusives
Interviews; Exclusives
Each week Managing IP speaks to a different IP lawyer about their life and career
Each week Managing IP speaks to a different IP lawyer about their life and career
Counsel at Sanofi reveal how they anticipated what questions US Supreme Court justices would throw at them and other challenges in the long-running case against Amgen
Alex Liu discusses the opportunities and challenges for pharma innovators in China and how he led his team to a record patent win
Law firm Susman Godfrey’s John Lahad explains how his firm and its co-counsel snagged a $42 million verdict for the University of Texas System and TissueGen
Dagg tells Managing IP about being starstruck when dealing with Nobel Prize-winning inventors, and how she deals with self-doubt
-
Weekly take: No harm in senators exploring patent alternatives
A proposed study into delinkage may not amount to much, and must be backed by strong evidence, but it can’t hurt to look into the issue -
Opinion: Indian domestic policy must match WTO stand on IP waivers
India has been both urging for vaccine waivers before the WTO and refusing compulsory licensing in the country, but it’s not helping anyone